NOVATO, Calif. (AP) — NOVATO, Calif. (AP) — Ultragenyx Pharmaceutical Inc. (RARE) on Tuesday reported a loss of $115 million in its second quarter.
On a per-share basis, the Novato, California-based company said it had a loss of $1.17.
The results exceeded Wall Street expectations. The average estimate of 11 analysts surveyed by Zacks Investment Research was for a loss of $1.27 per share.
The biotechnology company posted revenue of $166.5 million in the period, also exceeding Street forecasts. Eight analysts surveyed by Zacks expected $161.7 million.
Ultragenyx expects full-year revenue in the range of $640 million to $670 million.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on RARE at https://www.zacks.com/ap/RARE
Copyright © 2026 The Associated Press. All rights reserved. This material may not be published, broadcast, written or redistributed.
